Immunic (IMUX)

NASDAQ:IMUX

IMUX

Immunic

RESEARCH TOOLSreports

Want to see IMUX full AI Analyst Report?

Immunic (IMUX) Stock Forecast & Price Target

2,234 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMUX Analyst Ratings

Strong Buy

6 Buy

1 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Immunic

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMUX Stock 12 Month Forecast

Average Price Target

$39.80

▲(3880.00% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Immunic in the last 3 months. The average price target is $39.80 with a high forecast of $70.00 and a low forecast of $22.00. The average price target represents a 3880.00% change from the last price of $1.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","71":"$71","20.75":"$20.8","37.5":"$37.5","54.25":"$54.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,20.75,37.5,54.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.65,14.292307692307693,18.934615384615384,23.57692307692308,28.21923076923077,32.861538461538466,37.503846153846155,42.146153846153844,46.78846153846154,51.430769230769236,56.073076923076925,60.715384615384615,65.35769230769232,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.65,11.96923076923077,14.288461538461538,16.607692307692307,18.926923076923075,21.246153846153845,23.565384615384616,25.88461538461538,28.20384615384615,30.52307692307692,32.84230769230769,35.161538461538456,37.480769230769226,{"y":39.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.65,10.6,11.55,12.5,13.45,14.4,15.35,16.3,17.25,18.2,19.15,20.1,21.049999999999997,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.904,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.315,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.599,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.788,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.337,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.539,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.599,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.65,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$70.00

Average Price Target$39.80

Lowest Price Target$22.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Boobalan Pachaiyappan

Roth MKM

$11.28→$26

Buy

2500.00%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and Hinge Health, Inc. Class A (NYSE: HNGE)

Sam Slutsky

LifeSci Capital

$56

Buy

5500.00%

Upside

Initiated

05/04/26

Immunic initiated with an Outperform at LifeSci CapitalImmunic initiated with an Outperform at LifeSci Capital

Matthew Caufield

H.C. Wainwright

$5→$22

Buy

2100.00%

Upside

Reiterated

04/30/26

Immunic price target adjusted to $22 from $5 at H.C. WainwrightImmunic price target adjusted to $22 from $5 at H.C. Wainwright

Myles Minter

William Blair

―

Buy

―

Reiterated

04/22/26

Immunic Buy Rating: Vidofludimus Calcium’s Differentiated Efficacy and Safety Profile vs. BTK Inhibitors in Relapsing MS

Paul Matteis

Stifel Nicolaus

$25

Buy

2400.00%

Upside

Initiated

04/17/26

Immunic initiated with a Buy at StifelImmunic initiated with a Buy at Stifel

Jason Kolbert

D. Boral Capital

―

Hold

―

Downgraded

04/15/26

Immunic downgraded to Hold from Buy at D. Boral CapitalImmunic downgraded to Hold from Buy at D. Boral Capital

Yatin Suneja

Guggenheim

$70

Buy

6900.00%

Upside

Initiated

03/24/26

Immunic initiated with a Buy at GuggenheimImmunic initiated with a Buy at Guggenheim

Rudy Li

Wolfe Research

$30

Buy

2900.00%

Upside

Initiated

12/31/25

Immunic (IMUX) Has a New Rating from Chardan Capital

Aydin Huseynov

Ladenburg Thalmann & Co.

$30

Buy

2900.00%

Upside

Initiated

10/16/25

Immunic initiated with a Buy at LadenburgImmunic initiated with a Buy at Ladenburg

Faisal Khurshid

Jefferies

―

Buy

―

Reiterated

09/25/25

William Wood

B. Riley Securities

$50

Buy

4900.00%

Upside

Reiterated

07/01/25

B.Riley Financial Remains a Buy on Immunic (IMUX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Boobalan Pachaiyappan

Roth MKM

$11.28→$26

Buy

2500.00%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and Hinge Health, Inc. Class A (NYSE: HNGE)

Sam Slutsky

LifeSci Capital

$56

Buy

5500.00%

Upside

Initiated

05/04/26

Immunic initiated with an Outperform at LifeSci CapitalImmunic initiated with an Outperform at LifeSci Capital

Matthew Caufield

H.C. Wainwright

$5→$22

Buy

2100.00%

Upside

Reiterated

04/30/26

Immunic price target adjusted to $22 from $5 at H.C. WainwrightImmunic price target adjusted to $22 from $5 at H.C. Wainwright

Myles Minter

William Blair

―

Buy

―

Reiterated

04/22/26

Immunic Buy Rating: Vidofludimus Calcium’s Differentiated Efficacy and Safety Profile vs. BTK Inhibitors in Relapsing MS

Paul Matteis

Stifel Nicolaus

$25

Buy

2400.00%

Upside

Initiated

04/17/26

Immunic initiated with a Buy at StifelImmunic initiated with a Buy at Stifel

Jason Kolbert

D. Boral Capital

―

Hold

―

Downgraded

04/15/26

Immunic downgraded to Hold from Buy at D. Boral CapitalImmunic downgraded to Hold from Buy at D. Boral Capital

Yatin Suneja

Guggenheim

$70

Buy

6900.00%

Upside

Initiated

03/24/26

Immunic initiated with a Buy at GuggenheimImmunic initiated with a Buy at Guggenheim

Rudy Li

Wolfe Research

$30

Buy

2900.00%

Upside

Initiated

12/31/25

Immunic (IMUX) Has a New Rating from Chardan Capital

Aydin Huseynov

Ladenburg Thalmann & Co.

$30

Buy

2900.00%

Upside

Initiated

10/16/25

Immunic initiated with a Buy at LadenburgImmunic initiated with a Buy at Ladenburg

Faisal Khurshid

Jefferies

―

Buy

―

Reiterated

09/25/25

William Wood

B. Riley Securities

$50

Buy

4900.00%

Upside

Reiterated

07/01/25

B.Riley Financial Remains a Buy on Immunic (IMUX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunic

3 Months

xxx

Success Rate

6/10 ratings generated profit

Average Return

+21.16%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +21.16% per trade.

1 Year

Myles MinterWilliam Blair

Success Rate

9/10 ratings generated profit

Average Return

+29.73%

Copying Myles Minter's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +29.73% per trade.

2 Years

xxx

Success Rate

9/10 ratings generated profit

Average Return

+29.13%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +29.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMUX Analyst Recommendation Trends

Rating

Jan 26

Feb 26

Mar 26

Apr 26

May 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMUX has received 9 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IMUX average Analyst price target in the past 3 months is 39.80.

Each month's total comprises the sum of three months' worth of ratings.

IMUX Financial Forecast

IMUX Earnings Forecast

Currently, no earnings data available.

No data currently available

IMUX Sales Forecast

Currently, no sales data available.

IMUX Stock Forecast FAQ

What is IMUX’s average 12-month price target, according to analysts?

Based on analyst ratings, Immunic’s 12-month average price target is 39.80.

What is IMUX’s upside potential, based on the analysts’ average price target?

Immunic has 3880.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMUX a Buy, Sell or Hold?

Immunic has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.

What is Immunic’s price target?

The average price target for Immunic is 39.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $22.00. The average price target represents 3880.00% Increase from the current price of $1.

What do analysts say about Immunic?

Immunic’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of IMUX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Immunic (IMUX) Stock Forecast & Price Target

IMUX Analyst Ratings

IMUX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immunic

IMUX Analyst Recommendation Trends

IMUX Financial Forecast

IMUX Earnings Forecast

IMUX Sales Forecast

IMUX Stock Forecast FAQ

Detailed List of Analyst Forecasts